Acutaas Chemicals Limited (BOM:543349)
2,544.35
+19.05 (0.75%)
At close: Mar 27, 2026
Acutaas Chemicals Revenue
Acutaas Chemicals had revenue of 3.93B INR in the quarter ending December 31, 2025, with 42.98% growth. This brings the company's revenue in the last twelve months to 12.15B, up 31.60% year-over-year. In the fiscal year ending March 31, 2025, Acutaas Chemicals had annual revenue of 10.07B with 40.34% growth.
Revenue (ttm)
12.15B
Revenue Growth
+31.60%
P/S Ratio
17.15
Revenue / Employee
13.82M
Employees
879
Market Cap
208.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 10.07B | 2.89B | 40.34% |
| Mar 31, 2024 | 7.17B | 1.01B | 16.33% |
| Mar 31, 2023 | 6.17B | 966.00M | 18.57% |
| Mar 31, 2022 | 5.20B | 1.80B | 52.71% |
| Mar 31, 2021 | 3.41B | 1.01B | 42.13% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 22.27B |
| Neuland Laboratories | 15.75B |
| Shilpa Medicare | 14.33B |
| Bajaj HealthCare | 6.12B |
| NGL Fine-Chem | 4.47B |
| Anlon Healthcare | 1.70B |
| Gujarat Themis Biosyn | 1.59B |
| Influx Healthtech | 1.24B |